Overview

Assessment of the Effect of Captopril Versus Combination of Captopril and Pentoxifylline on Reducing Proteinuria in Type 2 Diabetic Nephropathy

Status:
Completed

Trial end date:
2008-01-01

Target enrollment:

Participant gender:

Summary

Diabetic nephropathy is the most common cause of ESRD and has a great impact on mortality and morbidity of diabetic patients. Despite renoprotective effect of ACE inhibitors in diabetic patients they can not hinder the progression of renal disease completely. Pentoxifylline as a TNFa blocker may hinder progression of diabetic nephropathy in combination of captopril.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Shiraz University of Medical Sciences

Treatments:

Captopril
Pentoxifylline